Long noncoding RNA variations in cardiometabolic diseases

• Published in: Journal of human genetics Vol. 62; no. 1; pp. 97 - 104
• Main Authors: Dechamethakun, Sariya, Muramatsu, Masaaki
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.01.2017
• Subjects: Cardiovascular Diseases - genetics; Gene Expression Regulation; Genetic Predisposition to Disease - genetics; Genome, Human - genetics; Genome-Wide Association Study - methods; Humans; Obesity - genetics; Phenotype; Polymorphism, Single Nucleotide; RNA, Long Noncoding - genetics
• ISSN: 1434-5161; 1435-232X
• DOI: 10.1038/jhg.2016.70

Cardiometabolic diseases are characterized as a combination of multiple risk factors for cardiovascular disease (CVD) and metabolic diseases including diabetes mellitus, dyslipidemia, hypertension and abdominal obesity. This cluster of abnormalities individually and interdependently leads to atherosclerosis and CVD morbidity and mortality. In the past decade, genome-wide association studies (GWASs) have identified a series of cardiometabolic disease-associated variants that can collectively explain a small proportion of the variability. Intriguingly, the susceptibility variants imputed from GWASs usually do not reside in the coding regions, suggesting a crucial role of the noncoding elements of the genome. In recent years, emerging evidence suggests that noncoding RNA (ncRNA) is functional for physiology and pathophysiology of human diseases. These include microRNAs and long noncoding RNAs (lncRNAs) that are now implicated in human diseases. The ncRNAs can interact with each other and with proteins, to interfere gene expressions, leading to the development of many human disorders. Although evidence suggests the functional role of lncRNAs in cardiometabolic traits, the molecular mechanisms of gene regulation underlying cardiometabolic diseases remain to be better defined. Here, we summarize the recent discoveries of lncRNA variations in the context of cardiometabolic diseases.